CAT vs LLY: Which Is the Better Buy?

Side-by-side comparison of Caterpillar Inc. and Eli Lilly and Company β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-05-13.
Caterpillar Inc. Β· Industrials
$912.14
-47.9% upside to fair value
Grade D High Quality
VS
Eli Lilly and Company Β· Healthcare
$934.34
+17.6% upside to fair value
Grade B High Quality
QuantHub Verdict
LLY has more upside to fair value (+17.6%). LLY trades at a lower forward P/E (33.1x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric CAT LLY
Current Price $912.14 $934.34
Fair Value Estimate $475.00 $1,098.43
Upside to Fair Value -47.9% +17.6%
Market Cap $420.2B $882.8B
Forward P/E 44.9x 33.1x
EV / EBITDA 30.0x 27.9x
Price / Sales 5.9x 12.2x
Price / FCF 36.7x 65.0x
Revenue Growth YoY +22.2% +55.5%
Gross Margin 32.5% 82.7%
Operating Margin 16.6% 46.3%
Return on Equity 47.5% 101.3%
Dividend Yield 1.5% 0%
FCF Yield 2.73% 1.54%
Analyst Consensus Hold Strong Buy
Investment Thesis
CAT β€” Caterpillar Inc.
Caterpillar is the world's leading manufacturer of construction and mining equipment, with diversified revenue across Construction Industries, Resource Industries, Energy & Transportation, and Cat Financial. Q1 2026 results reported April 30 showed revenue of $17.4 billion (+22.2% YoY) and EPS of $5.50 (+30.3% YoY), driven by powerful demand from data center build-outs (large engine and power gen…
LLY β€” Eli Lilly and Company
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Accumulation Zones
Metric CAT LLY
Zone Low $356.00 $823.82
Zone High $404.00 $933.67
In Buy Zone? No No
← CAT Research    LLY Research β†’    All Research